Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BeOne
Fierce Pharma
Akeso's 34% overall survival win comes with caveats
While ivonescimab and chemo's 34% improvement on overall survival exceeded expectations, detailed data from Harmoni-6 are being picked apart.
Angus Liu
May 31, 2026 8:00am
BeOne shelves 5 cancer programs, halts ph. 2 arthritis trial
May 7, 2026 11:15am
BeOne signs $2B deal for option on preclinical trispecific
Apr 30, 2026 7:55am
Jefferies London conference earns reputation as 'JPM for Europe'
Nov 18, 2025 10:00am
Fierce Pharma
Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC
Oct 19, 2025 10:45am
BeOne asset hits primary endpoint, tees up blood cancer filings
Aug 29, 2025 9:50am
